Science & Research
BioUtah Announces 2025 Life Sciences Award Winners Recognizing Utah's Healthcare Innovation Leaders
BioUtah will honor five distinguished individuals and companies at the 2025 Mayer Brown Utah Life Sciences Summit for their transformative contributions to healthcare innovation and economic growth in Utah's life sciences sector.
Quantumzyme Validates Sustainable Ibuprofen Manufacturing Process in Peer-Reviewed Publication
Quantumzyme Corp. has published research validating its enzymatic process for sustainable ibuprofen production, representing a significant advancement toward greener pharmaceutical manufacturing with reduced environmental impact.
Academic Research on Informal Higher Education Models Gains Global Attention
The Office of Count Jonathan David Nelson's research challenging traditional accreditation frameworks for informal universities is attracting international scholarly interest as education systems worldwide grapple with access and equity issues.
Innovotech Inc. Reports Record Third Quarter Revenue Driven by Antimicrobial Research and Laboratory Services Growth
Innovotech Inc. achieved record Q3-2025 revenue of $1.27 million, demonstrating strong performance across its antimicrobial research services and analytical laboratory divisions while positioning for continued expansion.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.
American Heart Association Launches Initiative to Accelerate Aortic Stenosis Diagnosis and Clinical Trial Access
The American Heart Association has launched a new initiative to improve early diagnosis of aortic stenosis and increase participation in clinical trials, potentially transforming care for this serious heart condition that often goes undiagnosed until advanced stages.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
Nvidia Introduces NVQLink System Connecting AI Chips to Quantum Computers
Nvidia's new NVQLink system bridges quantum computers with AI chips, potentially accelerating breakthroughs in medicine and materials science while positioning the company at the forefront of hybrid computing technology.
Cybin Chief Medical Officer to Present at Prestigious 2025 Milken Institute Health Summit
Cybin Inc.'s Chief Medical Officer will participate in the 2025 Milken Institute Future of Health Summit, highlighting the company's advanced clinical-stage mental health treatments and their potential to address significant unmet medical needs.
Quick Bystander CPR Within Five Minutes Nearly Doubles Pediatric Cardiac Arrest Survival
New research shows that initiating CPR within five minutes of a child's cardiac arrest can nearly double survival rates, highlighting the critical importance of immediate bystander intervention for pediatric emergencies.
Optimal Cardiovascular Health May Offset Dementia Risk in Type 2 Diabetes Patients
New research suggests that maintaining optimal cardiovascular health through the American Heart Association's Life's Essential 8 metrics can significantly reduce the risk of cognitive decline and dementia in people with Type 2 diabetes, even for those with high genetic risk.
Hidden Atrial Dysfunction Identified as Stroke Risk Factor in Heart Muscle Disease Patients
A new study reveals that people with transthyretin amyloid cardiomyopathy face significantly higher stroke risk when they have atrial electromechanical dysfunction, and researchers have developed a noninvasive assessment tool to identify those who might benefit from preventive treatments.
Long-Term Melatonin Use Linked to Increased Heart Failure Risk in Insomnia Patients, Study Finds
A preliminary study suggests adults with insomnia who used melatonin supplements for at least one year had significantly higher rates of heart failure diagnosis, hospitalization and death compared to non-users, raising important safety concerns about the widely available sleep aid.
Combining Healthy Lifestyle Habits with GLP-1 Medications Reduces Cardiovascular Risk in Type 2 Diabetes Patients
A study of over 63,000 veterans with Type 2 diabetes found that combining GLP-1 receptor agonist medications with at least six healthy lifestyle habits reduced cardiovascular event risk by 50% compared to standard care alone.
Combined Biomarker Analysis Reveals Triple Heart Attack Risk in High-Risk Individuals
A new study shows that analyzing three specific biomarkers together can identify individuals with nearly triple the risk of heart attack, potentially enabling earlier intervention and personalized prevention strategies.
Low-Dose Aspirin Shows Cardiovascular Benefits for High-Risk Type 2 Diabetes Patients
A preliminary study suggests adults with Type 2 diabetes and moderate-to-high cardiovascular risk who take low-dose aspirin experience significantly lower rates of heart attack, stroke, and death compared to non-users, though bleeding risks require careful consideration.
Nighttime Light Pollution Linked to Increased Heart Disease Risk Through Brain Stress Response
A new study reveals that exposure to artificial light at night increases heart disease risk by triggering stress-related brain activity and arterial inflammation, highlighting light pollution as a modifiable environmental health factor.
Foremost Clean Energy Reports Higher Uranium Grades at Saskatchewan Property
Foremost Clean Energy's final assay results from its Hatchet Lake Uranium Property confirm significantly higher uranium grades, potentially indicating proximity to a larger mineralizing system in the Athabasca Basin region.
Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
Oncotelic Therapeutics to Present Novel Breast Cancer Treatment Data at 2025 Symposium
Oncotelic Therapeutics will present clinical data for its investigational breast cancer treatment Sapu003 at the 2025 San Antonio Breast Cancer Symposium, potentially offering improved efficacy and reduced toxicity for patients with HR⁺/HER2⁻ metastatic breast cancer.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
AMD and IBM Partnership Advances Quantum Computing Error Correction Using Standard Chips
AMD shares surged nearly 8% after IBM announced that existing AMD processors can run critical quantum computing error correction algorithms, marking a significant advancement in making quantum technology more commercially viable.
Nanomedicine Breakthroughs Reshape Cancer Treatment Through Enhanced Drug Delivery
Advances in nanomedicine delivery systems are addressing critical limitations in cancer therapy by improving drug bioavailability and targeting while reducing toxicity, potentially transforming treatment standards across the oncology landscape.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
Quantum Art Achieves Breakthrough in Quantum Circuit Efficiency Through NVIDIA Partnership
Quantum Art's collaboration with NVIDIA has resulted in 10X circuit depth compression and 30% error reduction, accelerating the path toward commercially viable quantum computing applications.